Skip to main content

anti-pd-1/anti-tgfbrii bispecific antibody inca33890

Generic: Anti-PD-1/Anti-TGFbRII Bispecific Antibody INCA33890

anti-pd-1/anti-tgfbrii bispecific antibody inca33890: 3 clinical trials tracked.

anti-pd-1/anti-tgfbrii bispecific antibody inca33890 evidence translation

What we can confirm

3 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-pd-1/anti-tgfbrii bispecific antibody inca33890, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 1 study sponsors
Clinical Trials (3)

A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

NCT07284849·Phase 3·INCY
Recruiting

Primary endpoint: Progression-Free Survival (PFS)

InterventionalRandomizedquadruple700 targetStarted 2026-03Completion 2029-0950 sites · United StatesIncyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

NCT06179160·Phase 1·INCY
Recruiting

Primary endpoint: Number of participants with Dose Limiting Toxicities (DLTs)

Interventionalopen710 targetStarted 2024-01Completion 2027-0134 sites · Australia, Belgium, Canada, France…Incyte Corporation

A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

NCT05836324·Phase 1·INCY
Recruiting

Primary endpoint: Dose Limiting Toxicities (DLTs)

Interventionalopen570 targetStarted 2023-07Completion 2029-0539 sites · China, Denmark, France, Italy…Incyte Corporation